TD2

Move Your Drug to Market, Faster

As a contract research organization (CRO) dedicated to precision medicine for oncology, Translational Drug Development (TD2) works with innovative biotech and pharma companies to bring cancer treatments to patients as quickly as possible.

Support for Every Research Milestone

Our clients have exclusive access to an integrated suite of tools that support every research milestone, and efficiently—from preclinical process to regulatory compliance, trial management and an expansive patient database that makes recruiting easier than ever.

Minimize Risk During Drug Development

Protect your project against risk with advanced scientific tools built around cellular pathway interrogation, combination strategies and mutational context identification to give your new agents the greatest chance of success. After all, the future of oncology drug development depends on accurately defining the  clinical strategy that will give your drug an advantage in the clinic and then and aligning that strategy with clinical execution.

An Impact on Modern-Day Oncology

Born from the Translational Genomics Research Institute (TGen), TD2 was formed in 2003 as a subsidiary of TGen, and less than two years later, opened its doors on the campus of the Mayo Clinic in Scottsdale, Ariz. In our 15 years of business, we have helped more than 600 biotech and pharma companies, maintaining hundreds of client studies per year. Among them, our team has been involved in more than 600 first-in-man major oncology medicines, including numerous trials that have led to approvals in both rare and large indications.

Ask us how you can get your oncology drug to the market faster with TD2.